The President & CEO of Calithera Bio is Exercising Options

By Carrie Williams

Today, the President & CEO of Calithera Bio, Susan Molineaux, exercised options of Calithera Bio for $21.26K.

Following Susan Molineaux’s last CALA Buy transaction on December 20, 2016, the stock climbed by 7.0%. This recent transaction increases Susan Molineaux’s holding in the company by 3.59% to a total of $3.76 million.

Based on Calithera Bio’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $7.25 million and GAAP net loss of $6.07 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $8.54 million. The company has a one-year high of $20.05 and a one-year low of $2.90. Currently, Calithera Bio has an average volume of 564.6K.

Starting in January 2017, CALA received 5 Buy ratings in a row. Four different firms, including JMP Securities and Leerink Swann, currently also have a Buy rating on the stock.

The insider sentiment on Calithera Bio has been negative according to 14 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company, which focuses on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company was founded by James A. Wells and Susan M.